Correction: Cutting Edge: FcγRIII (CD16) and FcγRI (CD64) Are Responsible for Anti-Glycoprotein 75 Monoclonal Antibody TA99 Therapy for Experimental Metastatic B16 Melanoma

Authors :: Marcello Albanesi
David A. Mancardi
Lynn E. Macdonald
Bruno Iannascoli
Laurence Zitvogel
Andrew J. Murphy
Jeanette H. Leusen
Pierre Bruhns
Source :: The Journal of Immunology. 190:1381-1381
Publication Year :: 2013
Publisher :: The American Association of Immunologists, 2013.

Tools